Elevated ITGA1 levels in type 2 diabetes: implications for cardiac function impairment
Authors' conclusion
ITGA1 serves as a biomarker for monitoring cardiac structural and functional damage, can be used to accurately diagnose the presence of HFpEF, and can be used to predict potential deterioration in cardiac structure and function as well as re-hospitalisation for individuals with type 2 diabetes. Its measurement holds promise for facilitating risk stratification and early intervention to mitigate the adverse cardiovascular effects associated with diabetes.
Study context
- Population
- Individuals with T2D, with and without heart failure with preserved ejection fraction (HFpEF)
- Exposure
- T2D with HFpEF vs T2D without HFpEF; higher vs lower plasma ITGA1 levels
- Outcome
- Plasma ITGA1 levels
- Follow-up
- Baseline
Methodological detailsproteomic analysis, median follow-up 30 months, multivariable linear and Cox regression
- Proteomic analysis
- Median follow-up 30 months
- Multivariable linear and Cox regression
Main finding
As reported in the abstract
- Significantly higher plasma ITGA1 levels in T2D with HFpEF than in T2D without HFpEF
- Elevated ITGA1 levels associated with left ventricular remodelling and impaired diastolic function
Observational data: associations, not effects.
Further findings
Deterioration of cardiac function · median follow-up 30 months
- Elevated ITGA1 levels independently correlated with deterioration of both diastolic and systolic cardiac functions (multivariable analysis)
Re-hospitalisation risk · median follow-up 30 months
- Higher baseline plasma ITGA1 levels independently predicted re-hospitalisation risk (HR)
- 2.331 (95% CI 1.387, 3.917), p=0.001
Left ventricular myocardial proteomics
- Increased ITGA1 levels affect cardiac fibrosis-related pathways, contributing to development and progression of HFpEF
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →